Crossref
Topical Roflumilast (Zoryve) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
PsoriasisDermatologic AgentsHumansAminopyridinesBenzamidesCyclopropanesTreatment OutcomeAdministration, TopicalAdministration, CutaneousSeverity of Illness Index
Stichwörter der Autor:innen
DalirespDovonexDuobriiEnstilarEucrisaSoriluxTaclonexVecticalVtamaWynzoraZoryveadverse effectsbetamethasonecalcipotrienecalcitriol
Substanzen
RoflumilastAminopyridinesBenzamidesCyclopropanesDermatologic Agents
Zitieren
APA
(2023). Topical Roflumilast (Zoryve) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668b
Vancouver
Topical Roflumilast (Zoryve) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668b
BibTeX
@article{euvimed2023,
title = {Topical Roflumilast (Zoryve) for Plaque Psoriasis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668b}
}
EUVIMED